Welcome to our dedicated page for CERo Therapeutics SEC filings (Ticker: CEROW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The CEROW SEC filings page on Stock Titan aggregates regulatory documents for CERo Therapeutics Holdings, Inc., giving investors direct access to the company’s official disclosures. CERo identifies itself in its S-1 as a Delaware corporation in the biological products sector, an emerging growth company and a smaller reporting company, and its filings describe a business centered on drug candidates, preclinical studies and clinical trials, including work on CER-1236.
Key filings include multiple Form 8-K current reports. An 8-K dated January 7, 2026 describes a press release providing a clinical update on a Phase 1 trial of CER-1236 in AML (CertainT-1), highlighting safety data and a platelet transfusion-free interval observed in a patient with myelodysplastic syndrome/AML. Other 8-Ks filed in December 2025 detail a new common stock purchase agreement and related registration rights agreement with an institutional investor, continuing an equity line program for the company’s common stock.
The page also includes Form S-1 registration statements. In its December 2025 S-1, CERo explains that its common stock is traded on the OTCQB under the symbol "CERO" and outlines the potential resale by Keystone Capital Partners, LLC of shares issued under common stock purchase agreements that form an equity financing arrangement. The S-1 discusses the committed equity financing structure, prior registration statements and the role of Keystone as a selling securityholder.
In addition, proxy materials such as the definitive proxy statement on Schedule 14A provide detail on proposed amendments to the certificate of incorporation for a reverse stock split, approval of issuances under Nasdaq Listing Rule 5635, and amendments to the 2024 Equity Incentive Plan. On Stock Titan, these filings are presented with AI-powered summaries that highlight the main topics of each document, helping readers quickly identify items related to clinical development, financing arrangements, capital structure changes and governance proposals, while still allowing full-text review of the underlying SEC reports.
CERO Therapeutics Holdings director Francois Eric received a stock option grant as equity compensation. The award covers options to buy 1,823,278 shares of Common Stock at an exercise price of $0.055 per share, held directly.
The options vest in full on the earlier of August 13, 2026 or the achievement of a specified clinical milestone in 2026, provided Eric remains in continuous service through the vesting date. The options expire on March 3, 2036, and following this grant he holds options for 1,823,278 underlying shares.
CERO Therapeutics Holdings director Francois Eric received a stock option grant as equity compensation. The award covers options to buy 1,823,278 shares of Common Stock at an exercise price of $0.055 per share, held directly.
The options vest in full on the earlier of August 13, 2026 or the achievement of a specified clinical milestone in 2026, provided Eric remains in continuous service through the vesting date. The options expire on March 3, 2036, and following this grant he holds options for 1,823,278 underlying shares.
CERO THERAPEUTICS HOLDINGS, INC. director Francois Eric has filed a Form 3, which is an initial statement of beneficial ownership of the company’s securities. The filing establishes his status as a reporting person and does not list any purchase, sale, or other transaction activity.
CERO THERAPEUTICS HOLDINGS, INC. director Francois Eric has filed a Form 3, which is an initial statement of beneficial ownership of the company’s securities. The filing establishes his status as a reporting person and does not list any purchase, sale, or other transaction activity.
CERo Therapeutics Holdings, Inc. files its annual report describing progress on CER-1236, an autologous engineered T cell therapy targeting TIM-4 ligand for cancer. The company is running a first-in-human Phase 1/1b trial in acute myeloid leukemia, with five patients treated as of March 2026 and no dose-limiting toxicities reported to date.
CER-1236 has received FDA Orphan Drug Designation and Fast Track Designation for AML, and the trial has been expanded to include myelodysplastic syndrome and myelofibrosis. A separate Phase 1 study in non-small cell lung cancer and ovarian cancer is anticipated to begin in 2026. As of April 14, 2026, 36,786,686 shares of common stock were outstanding.
CERo Therapeutics Holdings, Inc. files its annual report describing progress on CER-1236, an autologous engineered T cell therapy targeting TIM-4 ligand for cancer. The company is running a first-in-human Phase 1/1b trial in acute myeloid leukemia, with five patients treated as of March 2026 and no dose-limiting toxicities reported to date.
CER-1236 has received FDA Orphan Drug Designation and Fast Track Designation for AML, and the trial has been expanded to include myelodysplastic syndrome and myelofibrosis. A separate Phase 1 study in non-small cell lung cancer and ovarian cancer is anticipated to begin in 2026. As of April 14, 2026, 36,786,686 shares of common stock were outstanding.
CERO Therapeutics Holdings, Inc. entered into a financing deal by issuing a convertible promissory note to Keystone Capital Partners for a purchase price of $350,000, with a principal face value of $437,500. Under this Note, the company may borrow up to an aggregate $1,000,000.
The Note bears 10% annual interest, matures on April 9, 2027, and can be converted into common stock at the lender’s option at the lesser of $0.05 per share or 80% of the average of the five lowest intraday trading prices over the prior 20 days, subject to a 4.99% beneficial ownership cap.
The transaction was conducted as a private placement to an accredited investor under Section 4(a)(2) and Rule 506(b) of the Securities Act, and the company agreed to file a registration statement on Form S-1 or S-3 to cover resale of the conversion shares.
CERO Therapeutics Holdings, Inc. entered into a financing deal by issuing a convertible promissory note to Keystone Capital Partners for a purchase price of $350,000, with a principal face value of $437,500. Under this Note, the company may borrow up to an aggregate $1,000,000.
The Note bears 10% annual interest, matures on April 9, 2027, and can be converted into common stock at the lender’s option at the lesser of $0.05 per share or 80% of the average of the five lowest intraday trading prices over the prior 20 days, subject to a 4.99% beneficial ownership cap.
The transaction was conducted as a private placement to an accredited investor under Section 4(a)(2) and Rule 506(b) of the Securities Act, and the company agreed to file a registration statement on Form S-1 or S-3 to cover resale of the conversion shares.
CERO THERAPEUTICS HOLDINGS, INC. reports that Isaiah Tibbs beneficially owns 1,830,007 shares of Common Stock, representing 8.67% of the class. The filing states Tibbs has sole power to vote and sole dispositive power over all 1,830,007 shares.
CERO THERAPEUTICS HOLDINGS, INC. reports that Isaiah Tibbs beneficially owns 1,830,007 shares of Common Stock, representing 8.67% of the class. The filing states Tibbs has sole power to vote and sole dispositive power over all 1,830,007 shares.
CERO Therapeutics Holdings, Inc. entered into a financing agreement by issuing a convertible promissory note to Keystone Capital Partners for a $750,000 purchase price with a principal face value of $937,500, allowing total borrowings up to $1,000,000. The note bears 10% annual interest, matures on July 9, 2027, and is convertible into common stock at the lesser of $0.05 per share or 80% of the average of the five lowest intraday trading prices over the prior 20 days, subject to a 4.99% beneficial ownership limit. The company plans to file a registration statement covering resale of conversion shares. CERO’s audit committee dismissed Wolf & Company, P.C. as independent auditor and appointed Salberg & Company, P.A., following prior audit reports that included a going concern explanatory paragraph and a material weakness in internal controls. The board also expanded from six to seven members and appointed Eric Francois as a new director, with an expectation he will stand for election at the 2026 annual meeting.
CERO Therapeutics Holdings, Inc. entered into a financing agreement by issuing a convertible promissory note to Keystone Capital Partners for a $750,000 purchase price with a principal face value of $937,500, allowing total borrowings up to $1,000,000. The note bears 10% annual interest, matures on July 9, 2027, and is convertible into common stock at the lesser of $0.05 per share or 80% of the average of the five lowest intraday trading prices over the prior 20 days, subject to a 4.99% beneficial ownership limit. The company plans to file a registration statement covering resale of conversion shares. CERO’s audit committee dismissed Wolf & Company, P.C. as independent auditor and appointed Salberg & Company, P.A., following prior audit reports that included a going concern explanatory paragraph and a material weakness in internal controls. The board also expanded from six to seven members and appointed Eric Francois as a new director, with an expectation he will stand for election at the 2026 annual meeting.
CERo Therapeutics Holdings, Inc. filed a current report to note that it has prepared a poster presentation for the Transplantation and Cellular Therapy Meetings beginning on February 4, 2026. The poster is included as Exhibit 99.1 and is described as summary information meant to be read alongside the company’s other SEC filings and public announcements.
The company states that the poster presentation speaks only as of its date and that it expressly disclaims any obligation to update it, even if circumstances change. The filing is administrative in nature and does not include financial results or major corporate transactions.
CERo Therapeutics Holdings, Inc. filed a current report to note that it has prepared a poster presentation for the Transplantation and Cellular Therapy Meetings beginning on February 4, 2026. The poster is included as Exhibit 99.1 and is described as summary information meant to be read alongside the company’s other SEC filings and public announcements.
The company states that the poster presentation speaks only as of its date and that it expressly disclaims any obligation to update it, even if circumstances change. The filing is administrative in nature and does not include financial results or major corporate transactions.
CERO Therapeutics Holdings, Inc. reported that the Nasdaq Listing and Hearing Review Council has affirmed a prior decision to delist the company’s securities from the Nasdaq Stock Market. The Council’s decision, dated January 29, 2026, upholds a panel ruling following an earlier trading suspension effective October 31, 2025.
This means the company’s common stock and related warrants will no longer trade on Nasdaq, which can affect trading liquidity and market visibility for shareholders. The filing does not describe any alternative listing venue in this excerpt.
CERO Therapeutics Holdings, Inc. reported that the Nasdaq Listing and Hearing Review Council has affirmed a prior decision to delist the company’s securities from the Nasdaq Stock Market. The Council’s decision, dated January 29, 2026, upholds a panel ruling following an earlier trading suspension effective October 31, 2025.
This means the company’s common stock and related warrants will no longer trade on Nasdaq, which can affect trading liquidity and market visibility for shareholders. The filing does not describe any alternative listing venue in this excerpt.
Cero Therapeutics Holdings, Inc. director Rolfe Lindsey reported receiving a stock option award. On January 7, 2026, he was granted a Stock Option (Right to Buy) covering 690,900 shares of common stock. The option has a conversion or exercise price of $0.055 per share, becomes exercisable on January 7, 2026, and carries an expiration date of January 6, 2036. Following this grant, Lindsey beneficially owned 690,900 derivative securities directly.
Cero Therapeutics Holdings, Inc. director Rolfe Lindsey reported receiving a stock option award. On January 7, 2026, he was granted a Stock Option (Right to Buy) covering 690,900 shares of common stock. The option has a conversion or exercise price of $0.055 per share, becomes exercisable on January 7, 2026, and carries an expiration date of January 6, 2036. Following this grant, Lindsey beneficially owned 690,900 derivative securities directly.
Cero Therapeutics Holdings, Inc. reported that director Kathleen LaPorte received a stock option grant. On January 7, 2026, she was awarded a Stock Option (Right to Buy) covering 690,900 shares of common stock with a conversion or exercise price of $0.055 per share. The option is listed as exercisable on January 7, 2026 and expires on January 6, 2036. Following this grant, LaPorte is shown as directly beneficially owning 690,900 derivative securities linked to the company’s common stock.
Cero Therapeutics Holdings, Inc. reported that director Kathleen LaPorte received a stock option grant. On January 7, 2026, she was awarded a Stock Option (Right to Buy) covering 690,900 shares of common stock with a conversion or exercise price of $0.055 per share. The option is listed as exercisable on January 7, 2026 and expires on January 6, 2036. Following this grant, LaPorte is shown as directly beneficially owning 690,900 derivative securities linked to the company’s common stock.